TRex Bio, Inc. (NASDAQ:TRXB) Stock Short Interest Report for October

TRex Bio, Inc. (NASDAQ:TRXB) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 195,608 shares. Based on an average daily volume of 183,613 shares, the short-interest ratio is currently 1.1 days.

Insider Buying and Selling at TRex Bio

In other TRex Bio news, major shareholder Alexandria Venture Investments bought 178,571 shares of the business’s stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the acquisition, the insider owned 1,346,501 shares in the company, valued at $18,851,014. This trade represents a 15.29% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

TRex Bio Stock Performance

NASDAQ:TRXB opened at $13.74 on Friday. TRex Bio has a 1 year low of $13.10 and a 1 year high of $16.56.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.